Evidence map›Paper›PMID 36941723›Full record

ArticleItalian journal of pediatrics2023

Paraneoplastic pemphigus and Castleman's disease: a case report and a revision of the literature.

Mariangela Irrera, Elena Bozzola, Antonello Cardoni, Rita DeVito, Andrea Diociaiuti, Maya El Hachem, Katia Girardi, Alessandra Marchesi, Alberto Villani

Open access · goldFull text readCase Reports
In one paragraph

Article in Italian journal of pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Mariangela IrreraPediatric Unit, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Elena BozzolaPediatric Unit, IRCCS Bambino Gesù Children's Hospital, Rome, Italy. elena.bozzola@opbg.net.ORCID http://orcid.org/0000-0003-2586-019X
Antonello CardoniUnity of Pathology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Rita DeVitoUnity of Pathology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Andrea DiociaiutiDermatology Unit and Genodermatosis Unit, Genetics and Rare Diseases Research Division, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Maya El HachemDermatology Unit and Genodermatosis Unit, Genetics and Rare Diseases Research Division, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Katia GirardiDepartment of Pediatric Hematology/Oncology and Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Alessandra MarchesiPediatric Unit, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Alberto VillaniPediatric Unit, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Bambino Gesù Children's Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn literature, a few reports described an association between paraneoplastic pemphigus (PNP) and Castelman's disease (CD), but no consensus have been proposed for the diagnostic-therapeutical approach. Aim of this study is to present a case report and explore the relationship between PNP and CD in pediatric patients, focusing on clinical manifestations, histopathological findings, treatment and outcome to find elements for an early diagnosis. CASE PRESENTATION: We present the clinical case of a 13 years old girl with a challenging diagnosis of PNP and CD who underwent therapy at first with Rituximab and then with Siltuximab, for the control of symptoms.

conclusionsReviewing literature, 20 clinical cases have been described in the pediatric age. Diagnosis may be challenging, requiring an average of 3 months (range from 3 weeks to 2 years). In all cases, the initial manifestations were mucocutaneous lesions, especially oral lesions with poor response to conventional treatment. Systemic symptoms may be present as well. Therapeutical approach is still discussed with no consensus. Almost all patients received corticosteroids with poor response. Other drugs including azathioprine, methotrexate, cyclosporine and monoclonal antibodies have been evaluated for the control of the disease. Further studies and experimental trials urge to define the diagnostic criteria and therapy protocol.

Indexed as

Castleman DiseasePemphigusAdolescentAdrenal Cortex HormonesAzathioprineChildFemaleHumansAdrenal Cortex HormonesAzathioprineCase reportCastelman’s diseaseChildParaneoplastic pemphigusTherapy

Identifiers

PMID36941723
PMCPMC10029234
OpenAlexW4328047977

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read35
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.